- Home
- ZDAI vs QNCX Comparison
ZDAI vs QNCX Comparison
Compare ZDAI & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZDAI | QNCX |
|---|---|---|
| Founded | 2022 | 2012 |
| Country | Hong Kong | United States |
| Employees | 33 | N/A |
| Industry | General Bldg Contractors - Nonresidential Bldgs | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.5M | 19.9M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | ZDAI | QNCX |
|---|---|---|
| Price | $2.20 | $1.28 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 149.7K | ★ 40.1M |
| Earning Date | 05-15-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $0.08 |
| 52 Week High | $11.48 | $4.55 |
Technical Indicators
Market Signals| Indicator | ZDAI | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 32.23 | 64.88 |
| Support Level | $0.33 | $1.17 |
| Resistance Level | $4.10 | $1.50 |
| Average True Range (ATR) | 0.30 | 0.11 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 29.04 | 26.39 |
Price Performance
Historical ComparisonAbout ZDAI Primega Group Holdings Limited Ordinary Shares
DirectBooking Technology Co Ltd, formerly Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.